Form SCHEDULE 13D - General Statement of Acquisition of Beneficial Ownership:
SEC Accession No. 0001193125-26-174330
Filing Date
2026-04-23
Accepted
2026-04-23 20:01:50
Documents
2
X0202

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D  
1 primary_doc.xml SCHEDULE 13D 13370
2 EX-99.B ck0000000000-ex99_b.pdf EX-99.B 137052
  Complete submission text file 0001193125-26-174330.txt   203984
Mailing Address 200 CLARENDON STREET BOSTON MA 02116
Business Address 200 CLARENDON STREET BOSTON MA 02116 6175162000
BCLS Fund IV Investments, L.P. (Filed by) CIK: 0002015454 (see all company filings)

EIN.: 933190582 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D

Mailing Address 180 THIRD AVENUE 4TH FLOOR WALTHAM MA 02451
Business Address 180 THIRD AVENUE 4TH FLOOR WALTHAM MA 02451 508-440-9475
Kailera Therapeutics, Inc. (Subject) CIK: 0002096997 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D | Act: 34 | File No.: 005-95629 | Film No.: 26890128
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)